Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00503_DB00541_nanopub.RAd3Hd8TQU0HfYIJHXnjVes-DnPj3XBMzRVn3FCU1b-Jk#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00503_DB00541 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00503_DB00541 label "DDI between Ritonavir and Vincristine - Ritonavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ritonavir is initiated, discontinued or dose changed. [drugbank_resource:DB00503_DB00541]" assertion.
- drugbank_resource:DB00503_DB00541 identifier "drugbank_resource:DB00503_DB00541" assertion.
- drugbank_resource:DB00503_DB00541 title "DDI between Ritonavir and Vincristine - Ritonavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ritonavir is initiated, discontinued or dose changed." assertion.
- drugbank:DB00541 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00503_DB00541 assertion.
- drugbank:DB00503 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00503_DB00541 assertion.